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S U M M A R Y
Background: Ciproﬂoxacin (CPFX) is a potential alternative in patients with febrile neutropenia (FN)
because of its activity against Gram-negative organisms. We conducted a non-inferiority, open-label,
randomized controlled trial comparing intravenous CPFX and cefepime (CFPM) for FN patients with
hematological malignancies.
Methods: Patients aged from 15 to 79 years with an absolute neutrophil count of <0.500  109/l were
eligible, and were randomized to receive 300 mg of CPFX or 2 g of CFPM every 12 h. Initial treatment
efﬁcacy, overall response, and early toxicity were evaluated.
Results: Fifty-one episodes were included in this trial, and 49 episodes (CPFX vs. CFPM: 24 vs. 25) were
evaluated. Treatment efﬁcacy at day 7 was signiﬁcantly higher in the CFPM group (successful clinical
response: nine with CPFX and 19 with CFPM; p = 0.007). The response was better in high-risk patients
with neutrophil counts of 0.100  109/l (p = 0.003). The overall response during the study period was
similar between the CPFX and CFPM groups (p = 0.64). Adverse events were minimal, and all patients
could continue the treatment.
Conclusions: We could not prove the non-inferiority of CPFX in comparison with CFPM for the initial
treatment of FN. CFPM remains the standard treatment of choice for FN.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The goal of initial empiric antibiotic therapy for febrile
neutropenia (FN) with hematologic malignancies is to prevent
serious morbidity and mortality due to bacterial pathogens, until
the results of blood cultures are available to guide more precise
antibiotic choices. Although Gram-positive bacteria have increased
as pathogens in FN during the past 20 years, Gram-negative
bacteria are associated with a greater mortality.1 In particular,
Pseudomonas aeruginosa infection is associated with a higher
mortality,2 and coverage of this organism remains an essential
component of the initial empiric antibiotic regimen. A commonly
used therapy for FN is a combination of b-lactam antibiotic and* Corresponding author. Tel.: +81 52 719 1974; fax: +81 52 719 1973.
E-mail address: r-suzuki@med.nagoya-u.ac.jp (R. Suzuki).
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http://dx.doi.org/10.1016/j.ijid.2012.12.005aminoglycoside, which offers a broad spectrum of initial coverage,
including P. aeruginosa.3,4
Although combination therapy with a b-lactam antibiotic and
an aminoglycoside has been reported to be highly effective for
neutropenic patients,3,4 aminoglycosides have some serious
adverse effects such as renal dysfunction and ototoxicity.
Antibiotics as monotherapy are generally less toxic, less costly,
and more convenient to administer to patients than combination
therapy,5 so monotherapy with a fourth-generation cephem or
carbapenem has been applied and compared to combination
therapy in randomized controlled trials; these did not show
diminished effectiveness of monotherapy.6–9 Monotherapy is now
also recommended as standard therapy in the Infectious Diseases
Society of America (IDSA) guidelines 2010.10
However, the incidence of drug-resistant bacterial species in
the institute should be taken into consideration when using
monotherapy, because resistant bacteria would tend to result inses. Published by Elsevier Ltd. All rights reserved.
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combination therapy.5 In fact, extended-spectrum b-lactamase
(ESBL)- and metallo-b-lactamase-producing Gram-negative bac-
teria are emerging at an increasing rate, and these cause signiﬁcant
mortality.11–13 In this context, alternative effective regimens other
than b-lactams are warranted for neutropenic patients to
overcome the resistant bacteria.
Ciproﬂoxacin (CPFX) is an attractive drug that has wide coverage
against Gram-negative organisms including P. aeruginosa, good
pharmacokinetic characteristics, and an absence of the need for drug
level monitoring.14,15 A number of studies have demonstrated that
CPFX combined with a b-lactam is effective for neutropenic
patients.16–18 Furthermore, CPFX inhibits DNA gyrase of prokaryotic
organisms,14 and the drug mechanism is completely different from
that ofb-lactams. Therefore, CPFX may be active for some organisms
resistant to b-lactams and it would be acceptable for those who are
allergic tob-lactams.19 In this context, CPFX is a potential alternative
for the empiric treatment of patients with FN. However, mono-
therapy with CPFX has been less well reported and is not well
established in the treatment of FN patients.
To assess the possibility of increasing the choice of initial
treatment for FN, we designed a randomized controlled trial of
intravenous CPFX vs. cefepime (CFPM) in FN patients. This trial
aimed to prove its non-inferiority compared to CFPM, a standard
therapy for FN.
2. Materials and methods
From January 2005 to December 2009, a non-inferiority, open-
label, randomized, multicenter trial was conducted to evaluate the
efﬁcacy of intravenous CPFX for FN. The study was approved by
both the protocol committee and the institutional review board of
each institution. Informed consent was obtained from all patients
before registration in this study. The study was registered in the
University Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR number: UMIN C000000083) and at Clinical-
Trials.gov (identiﬁer: NCT00137787). Randomization was per-
formed automatically, stratiﬁed by primary disease and balanced
in each institute, at the time of enrollment, on a website operated
by the Center for Supporting Hematology-Oncology Trials (C-
SHOT) data center.
3. Deﬁnitions
Fever was deﬁned as an axillary temperature of not less than
38 8C, or of 37.5–38 8C sustained for more than 1 h. Resolution of
fever was deﬁned as a maximum temperature of less than 37.5 8C
sustained for three successive days, and the ﬁrst day was deﬁned as
the date the fever disappeared. Fever was considered to be worse
when at least one of the following criteria was met: more than 1 8C
elevation in maximum body temperature, change from remittent
fever to continued fever, emergence of new infectious foci, blood
culture positivity after administration of antibiotics, more than
10% fall in arterial O2 pressure or oxygen saturation, and a decline
of performance status.
Episodes of fever were classiﬁed as microbiologically docu-
mented infection, clinically documented infection, or fever of
unknown origin (FUO). Microbiologically documented infection
was deﬁned as the isolation of microorganisms. Clinically
documented infection was considered when there were foci of
infection on physical examination or clinical data, without
microbiological documentation. FUO was considered when there
was no clinical or microbiological evidence of infection in a febrile
episode.
Neutropenia was deﬁned as an absolute neutrophil count
(ANC) of <0.500  109/l or that from 0.500  109/l to0.100  109/l showing a decline compared with the level at
the last examination. Recovery of neutropenia was deﬁned as an
ANC of 0.500  109/l sustained for 24 h after ANC had dropped
to <0.500  109/l. The ﬁrst day was considered to be the
recovery date.
3.1. Patients
Patients had to meet all of the following criteria for inclusion
in the study: age 15–79 years, at least one episode of fever,
neutropenia within 72 h, total bilirubin of 2.0 times the upper
limit of normal (ULN) or less, creatinine of 1.5 times ULN or less,
and giving informed consent. Patients were excluded if they had
a history of allergic reaction to antibiotics, HIV infection, were
pregnant or lactating, had a family history of deafness, had
received antibiotics in the last 14 days, had received an
antifungal or antiviral agent, ketoprofen, or sodium valproate,
were infected with bacteria resistant to agents used in this
study, were in septic shock, or other inappropriate cases as
judged by a physician. If the ANC did not recover to
1.000  109/l after the last episode of fever, the patient was
also ineligible for this study.
3.2. Treatment
Patients received 300 mg of CPFX or 2 g of CFPM intrave-
nously every 12 h immediately upon the development of FN.
Treatment was continued until patients met the criteria for
treatment discontinuation as follows: fever absent for more than
48 h (ANC of 0.500  109/l) or for more than 5 days (ANC from
0.100  109/l to 0.500  109/l) without any symptoms. If the
associated symptoms worsened or were sustained during the
study period, the treatment was modiﬁed according to the study
protocol (Figure 1). From 72 h to 120 h after the study started, an
aminoglycoside was added to the treatment if fever symptoms
worsened. From 120 h to 168 h, the initial antibiotic was
discontinued and the combination therapy of carbapenem
(meropenem or imipenem), aminoglycoside, and antifungal
agents was started. After 168 h, patients were allowed to receive
any treatment as required if fever persisted. Patients could
receive granulocyte colony-stimulating factor, if required, at any
time.
3.3. Clinical and laboratory evaluations
Clinical symptoms were monitored daily. Blood cell counts
were obtained at least twice a week, and biochemical parameters
were measured at least once a week. Blood culture, serum
endotoxin, b-D-glucan, and chest radiographs were obtained
before starting antibacterial therapy and in the case of a sustained
or worsened pattern of fever.
3.4. Response criteria
The primary endpoint of this study was the rate of the initial
treatment success at day 7. Response to treatment at day 7 was
divided into four groups as follows: very effective: fever
disappeared with a temperature below 37.5 8C within 4 days
and an afebrile state remained for more than 3 days; effective:
maximum temperature decreased 1 8C or more within 4 days and
an afebrile (below 37.5 8C) state persisted for 7 days; partial
response: maximum temperature decreased 1 8C or more within 7
days accompanied by the improvement of clinical symptoms; not
effective: maximum temperature did not decrease by 1 8C or more
within 7 days and/or no improvement of febrile symptoms. The
response to treatment was categorized as a success if patients were
Figure 1. Treatment algorithm for febrile neutropenia. For febrile neutropenia, we treated patients according to the treatment algorithm. Treatment evaluation and treatment
modiﬁcation were performed as shown (CPFX, ciproﬂoxacin; CFPM, cefepime; ET, endotoxin; b-D, b-D-glucan; X-P, X-ray picture; AMK, aminoglycoside; MEPM,
meropenem; IPM/CS, imipenem/cilastatin).
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day 7.
We also evaluated the overall response rate at day 21 as a
secondary endpoint. If patients were able to discontinue the
treatment according to the criteria described above, it was
considered to be successful.
3.5. Adverse events
Adverse events, regardless of whether they appeared to be
related to the use of the study medication, were carefully recorded
throughout the study. Causal relationships between the study
drugs and adverse events were analyzed using six stages:
deﬁnitive, probable, possible, unlikely, not related, and not
assessable. Adverse events were considered related to the study
drug if the stage was deﬁnitive, probable, or possible. The severity
of the adverse events was classiﬁed according to the National
Cancer Institute Common Toxicity Criteria version 2.0 (http://
ctep.cancer.gov/).
3.6. Statistical analysis
Percentages of comparability of the treatment arms, treatment
response, and treatment modiﬁcation were compared by Chi-
square test or Fisher’s exact test. Quantitative variables were
analyzed by Mann–Whitney test.
The success rates of the CFPM and CPFX arms were estimated to
be 50% and 60%, respectively.7 The d value of non-inferiority was
set to be 15% in accordance with previous reports. The CFPM arm
was the reference. To prove the non-inferiority of the CPFX arm, the
lower limit of the 95% conﬁdence interval (CI) of the difference of
efﬁcacy should exceed the d value. With a statistical power of 90%
and a one-sided type I error of 2.5%, the number of patients
required for this study was calculated to be 82 in each arm using a
binominal analysis method. Therefore, the total number of accrual
was planned to be 100 patients in each arm.4. Results
4.1. Characteristics of the study population
From January 2005 to December 2009, 51 patients were
registered from seven participating institutes in Japan. Forty-nine
patients (24 in the CPFX arm and 25 in the CFPM arm) were eligible
for assessment, but two patients were excluded because they did
not meet the inclusion criteria. Ten patients were enrolled in the
study more than once via different episodes of FN. Although we
planned to include 200 patients, this study was closed in December
2009 due to slow accrual.
The clinical characteristics of the patients in both treatment
arms are listed in Table 1. The distribution of patient sex, diagnosis,
treatment for primary disease, neutrophil count at randomization,
and duration of neutropenia did not differ between the arms. Acute
leukemia was the most common disease in this study (55.1%).
Patient age was younger in the CPFX arm than in the CFPM arm
(median age 53 vs. 61 years; p = 0.02). Four patients were excluded
from further analysis of the duration of neutropenia because their
neutrophil counts did not exceed 0.500  109/l (n = 3), or their
neutrophil counts did not drop below 0.500  109/l (n = 1).
4.2. Type of infection and microbiological outcomes
Of 49 episodes, the responsible bacterium was identiﬁed in 11
(22.4%). A Gram-positive coccus was cultured in eight episodes,
consisting of one each of methicillin-sensitive Staphylococcus
aureus, Staphylococcus haemolyticus, and Staphylococcus epidermi-
dis, and ﬁve Streptococcus species (Table 2). A Gram-negative
bacillus was isolated in three episodes: one each for P. aeruginosa,
Klebsiella pneumoniae, and Pasteurella (Table 2). Ten of the 11
episodes were diagnosed with sepsis and one with meningitis. The
other two clinically documented episodes were diagnosed with
pneumonia and peritonitis, but no responsible organisms were
identiﬁed.
Table 1
Characteristics of patients enrolled in the study
Characteristic CPFX (n = 24) CFPM (n = 25) p-Value
Patient sex
Male 16 (67%) 14 (56%) 0.44
Female 8 (33%) 11 (44%)
Patient age
Median 53 61 0.02
Range 21–65 21–79
Diagnosis
AML 9 (38%) 11 (44%) 0.72
ALL 4 (17%) 3 (12%)
CML 3 (13%) 2 (8%)
MDS 1 (4%) 0
ML 5 (21%) 5 (20%)
MM 1 (4%) 3 (12%)
ATLL 0 1 (4%)
Myeloid sarcoma 1 (4%) 0
Treatment for primary disease
HSCT 0 1 (4%) 0.32
Chemotherapy 24 (100%) 24 (96%)
Neutrophil count at start of study
<0.100  109/l 15 (63%) 18 (72%) 0.19
0.100–0.500  109/l 6 (25%) 7 (28%)
0.501–1.000  109/l 3 (13%) 0
Duration of neutropenia
7 days 5 (24%) 7 (29%) 0.75
>7days 16 (76%) 17 (71%)
CPFX, ciproﬂoxacin; CFPM, cefepime; AML, acute myeloid leukemia; ALL, acute
lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodys-
plastic syndrome; ML, malignant lymphoma; MM, multiple myeloma; ATLL, adult
T-cell leukemia/lymphoma; HSCT, hematopoietic stem cell transplantation.
Table 3
Treatment modiﬁcation
Treatment modiﬁcation CPFX (n = 24) CFPM (n = 25) p-Value
Initial treatment continued 10 (42%) 15 (60%) 0.20
Modiﬁcation
Initial treatment replaced 10 (42%) 5 (20%) 0.10
Add aminoglycoside 13 (54%) 8 (32%) 0.12
Add vancomycin 4 (17%) 0 0.05
Add antifungal agents 8 (33%) 7 (28%) 0.69
Add antiviral agents 2 (8%) 1 (4%) 0.61
CPFX, ciproﬂoxacin; CFPM, cefepime.
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Ten patients (41.7%) treated with CPFX and 15 patients (60.0%)
treated with CFPM received the same treatment without
modiﬁcation (Table 3). For the patients who were judged as
febrile by physicians, treatment modiﬁcations were performed
according to the algorithm described in Figure 1. In the CPFX arm,
an aminoglycoside was added to the treatment regimen for 13
patients (54.2%) and CPFX was replaced by other antibiotics for 10
patients (41.7%). In the CFPM arm, an aminoglycoside was added
for eight patients (32.0%) and CFPM was replaced for ﬁve patients
(20.0%). Vancomycin was added for four patients (16.7%) in the
CPFX arm, but not in the CFPM arm.
4.4. Efﬁcacy of CPFX and CFPM
The treatment was effective in nine patients (37.5%) in the CPFX
arm and 19 (76.0%) in the CFPM arm at day 7 (Figure 2). The
difference of the effective proportion was 38.5% (95% CI 64% to
13%), and the lower limit (64%) did not exceed the d value of
15%. Furthermore, the efﬁcacy was signiﬁcantly lower in the
CPFX arm (p = 0.007). However, the overall efﬁcacy at day 21 was
similar between the two arms (CPFX 83.3% vs. CFPM 88.0%,Table 2
Microbiological blood culture results on day 0
Infecting microorganisms CPFX (n = 24) CFPM (n = 25)
Gram-positive organisms 5 (21%) 3 (12%)
Coagulase-positive Staphylococcus 1 (4%) -
Coagulase-negative Staphylococcus 2 (8%) -
Streptococcus 2 (8%) 3 (12%)
Gram-negative organisms - 3 (12%)
Pseudomonas aeruginosa - 1 (4%)
Klebsiella pneumoniae - 1 (4%)
Pasteurella species - 1 (4%)
CPFX, ciproﬂoxacin; CFPM, cefepime.p = 0.64). Patients for whom treatment failed were rescued by
treatment modiﬁcation.
For patients from whom the responsible bacteria were
isolated, a treatment response at day 7 was achieved in 20.0%
in the CPFX arm and 66.7% in the CFPM arm (p = 0.12, Table 4).
Gram-positive coccus infection (16.3%) was more common than
Gram-negative bacillus infection (6.1%). The efﬁcacy was better in
the CFPM arm (66.7%) than in the CPFX arm (20.0%), but the
difference was not statistically signiﬁcant (p = 0.12). For patients
retaining FUO, a treatment response was achieved in 47.1% of
patients in the CPFX arm and 78.9% of patients in the CFPM arm
(p = 0.05, Table 4).
Since patients with prolonged neutropenia of more than 7 days
or profound neutropenia (ANC of 0.100  109/l) are regarded as at
high risk in the IDSA guidelines 2010,10 a subgroup analysis of this
population was also conducted. Fewer patients in the CPFX arm
than in the CFPM arm had a good clinical response (Table 4).
4.5. Adverse events
Table 5 shows all adverse events within 21 days in both arms.
Six events in the CPFX arm compared to two in the CFPM arm were
associated with the drug. The most common toxicity was liver
dysfunction (16.7% in the CPFX arm and 8.0% in the CFPM arm).
Two severe adverse events of grade 3 were observed in the CPFX
arm (liver dysfunction and skin rash), and one event in the CFPM
arm (liver dysfunction). All patients could continue the study
medication without cessation of the therapy due to adverse events.Figure 2. Clinical efﬁcacy of ciproﬂoxacin and cefepime. Initial treatment
evaluation showed a signiﬁcantly better response in the CFPM arm than in the
CPFX arm (76.0% vs. 37.5%, p = 0.007). Overall, treatment evaluation showed almost
the same efﬁcacy between the two arms (CPFX, ciproﬂoxacin; CFPM, cefepime).
Table 4
Response at day 7 by the cause of fever and severity of neutropenia
CPFX CFPM p-Value
Cause of fever
Microbiologically documented
infection
1/5 (20%) 4/6 (67%) 0.12
Sepsis 1/4 (25%) 4/6 (67%)
Meningitis 0/1 -
Clinically documented infection
(pneumonia and peritonitis)
0/2 - -
Unknown origin 8/17 (47%) 15/19 (79%) 0.05
Duration of neutropeniaa
>7 days 5/16 (31%) 13/17 (77%) 0.02
7 days 3/5 (60%) 5/7 (71%) 0.68
Baseline neutrophil count
0.100  109/l 5/15 (33%) 15/18 (83%) 0.003
>0.100  109/l 4/9 (44%) 4/7 (57%) 0.61
CPFX, ciproﬂoxacin; CFPM, cefepime.
a Four patients were excluded from the analysis because the neutrophil count did
not recover to 0.500  109/l (n = 3), or the neutrophil count did not drop to
<0.500  109/l (n = 1).
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The efﬁcacy and safety of CPFX monotherapy for neutropenic
patients has not been well investigated. One study showed that
patients treated with CPFX had a signiﬁcantly lower overall success
rate than those treated with piperacillin plus amikacin.20 In
contrast, another study comparing CPFX monotherapy with b-
lactam plus aminoglycoside showed that the response rate was
similar.19 Furthermore, a prospective randomized study compar-
ing ceftazidime and CPFX as initial therapy also demonstrated that
the levels of efﬁcacy were equal.21 These results imply that the role
of CPFX monotherapy for FN has been controversial and needs
further assessment because b-lactam-resistant organisms are on
the increase.
In this randomized, controlled, open-label trial, we could not
prove the non-inferiority of CPFX monotherapy compared withTable 5
Adverse events within 21 days
Adverse eventsb Grade Number of
patients in
CPFX group
(n = 24)
Number of
patients in
CFPM group
(n = 26)
Cardiovascular 1 0 2
Gastrointestinal 1 2 3
2 1 1
3 2 1
4 1 0
Liver 1 5 (2)a 10 (1)a
2 4 (2)a 0
3 1 (1)a 1 (1)a
Renal 1 1 0
Blood sugar 1 2 3
2 2 0
Electrolytes 1 3 4
2 1 1
3 2 0
Neurological 1 1 1
2 0 1
3 0 0
3 1 0
Cutaneous 1 0 1
2 2 1
3 1 (1)a 0
CPFX, ciproﬂoxacin; CFPM, cefepime.
a Numbers in the parenthesis indicate the drug-associated events (judged as
‘possible’ or more).
b Adverse events grade is based on the National Cancer Institute (NCI) Common
Toxicity Criteria version 2.0.CFPM. One of the possible reasons for this is that, although CPFX
has strong activity against Gram-negative rods, the coverage and
activity for Gram-positive cocci including viridans were insufﬁ-
cient.22,23 In fact, our microbiological data show that the treatment
success rate for Gram-positive organisms tended to be inferior in
the CPFX arm, and the use of vancomycin was applied only in the
CPFX arm.
Another possible reason is that the blood concentration of CPFX
might not be adequate because CPFX was administered at a dose of
600 mg/day in this study, a dose that is allowed under the health
insurance system in Japan. A recent study demonstrated that only
high-dose CPFX (regimens of 400 mg every 8 h or 400 mg every
12 h) can provide good coverage for pathogens with a minimum
inhibitory concentration (MIC) of 0.5 mg/ml.24 This was also
conﬁrmed by previous clinical studies, in which monotherapy with
CPFX at a low dose (400 mg/day) was not comparable to the
standard therapies, but CPFX at a relatively high dose (600 mg/day)
was equally effective.19,20,25 A precise pharmacokinetic study and
the provision of an appropriate concentration of CPFX might have
led to a better response for FN.26
Previous studies have demonstrated that various therapies of
CPFX combined with b-lactams such as benzylpenicillin,27
teicoplanin,28 and azlocillin,29 are comparable with the standard
therapy for neutropenic patients. In a meta-analysis comparing
CPFX plus b-lactam and aminoglycoside plus b-lactam, the former
showed better outcomes.17 Furthermore, CPFX plus b-lactam is
reported to be less toxic in terms of nephro- and oto-toxicities.30
These results suggest that the combination of CPFX with a b-
lactam may be a valuable alternative to the more commonly used
aminoglycoside plus b-lactam combination in the management of
FN.
Assessment of the risk of complications in severe infection is
important to determine the type of empiric antibiotic therapy (oral
vs. intravenous), the venue for treatment (inpatient vs. outpatient),
and the duration of antibiotic therapy.10 The IDSA guidelines have
demonstrated that monotherapy with oral CPFX is acceptable for
low-risk patients.10,31 On the other hand, the guidelines do not
recommend monotherapy with CPFX as standard therapy for high-
risk patients.10 We further tried to assess the link between initial
treatment response and risk status using both the duration of
neutropenia and the neutrophil count as simple biomarkers.7 Our
subgroup analysis showed that among patients at a ‘high risk’ of
neutropenia, those who received CPFX had signiﬁcantly lower
response rates at day 7. In contrast, no signiﬁcant difference was
found for low-risk patients. These results suggest that CPFX
monotherapy might be applicable for low-risk FN.
In terms of safety, the two agents appear to have similar safety
proﬁles. The most common adverse event possibly related to the
therapies was liver dysfunction, and all the patients could continue
therapy.
This trial was prematurely terminated due to slow patient
accrual, but not by the predeﬁned early stopping-rule of
superiority of CFPM. Prophylactic oral CPFX was not allowed in
this study, which might have hindered the accrual. The signiﬁcance
of prophylactic CPFX has been legitimized in recent years.10
Another possible reason is that this was an open-label randomized
controlled trial. Since physicians were able to observe the efﬁcacy
of the allocated agents, their impressions might have inﬂuenced
the slow accrual. Furthermore, the randomization procedure was
cumbersome for physicians because fever could occur at any time.
In conclusion, we could not verify the non-inferiority of
monotherapy with CPFX to that with CFPM at day 7, although
the overall response was similar in both arms. When selecting
monotherapy for the treatment of neutropenic patients, CFPM
remains the standard initial treatment of choice. CPFX is better for
prophylactic than empiric use.
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